In the past 30 years, the pharmaceutical industry has become the world's largest producer and exporter of raw materials. Pharmaceutical companies in the top 10 of the global market for raw materials in 2016, according to the us-based Transparent medical website, have made up six of the top 10 pharmaceutical companies. Zhejiang pharmaceutical companies make up four of the world's top 10 manufacturers of raw materials, indicating that zhejiang has become an important manufacturing and export base for raw materials in China.
Exports of commodities fell
According to the us medical website, sales of international raw materials were $127bn in 2014, up from $143bn in 2016. Among them, North America, 35% of the total market share of global pharmaceutical ingredients (apis), the asia-pacific region (including the United States and Canada) API sales market, accounting for the global active pharmaceutical ingredients, total market share of nearly six shows that active pharmaceutical ingredients in the asia-pacific region has become the largest sales market. Europe has been slow to grow in the traditional market for raw materials. Regional pharmaceutical markets in South America and Africa are growing weak.
Chinese medicine and health products import and export chamber of commerce reports that in 2016 China's total export 8.27 million tons of API product, the net increase of 13% over the previous year, but the overall exports of API prices fell by 11.59% last year. According to industry insiders, this is in line with the demand of the international market for raw materials, as well as the reduction of national health care in the United States and Europe, and the price of the raw materials in western countries. Europe and the us are, after all, the main importer of raw materials, in contrast to countries such as South America and Africa that import less raw materials.
Over the last few decades, China's exports of a vast amount of active pharmaceutical ingredients, amino acids such as glutamic acid, glucocorticoid hormones, all kinds of cephalosporin class of antibiotics and amoxicillin semi-synthetic penicillin, tetracycline, aminoglycoside antibiotics, large ring lactone class antibiotic, antipyretic analgesic drugs organic acid and citric acid as major products mainly sold to Europe and the United States developed countries, once the above API product prices, will hold down the overall price of our export API.
Because of European and American countries generally economy, its API importers to one thousand foreign API prices lower, and our country exporters in order to retain old customers often lower the export price (in quantity in benefits), because the domestic medicine companies serious excess capacity, no export is a dead end.
In recent years, the export of raw materials in China has become the norm. Fortunately, in a whirl of price cuts, API products in the last year China's exports also have some products export prices rose slightly, including gentamicin, polymyxin, large ring lactone class popular varieties of active pharmaceutical ingredients (such as erythromycin and azithromycin, clarithromycin, etc.), but its export quantity is not very big, API export overall impact is not big to our country.
The price of a wide variety of exports such as penicillin, tetracycline, erythromycin, citric acid, 6APA and 7ACA fell 3% to 5%. Falling prices of commodity exports are the main factors contributing to the overall decline in the export of raw materials.
The production of raw materials and preparations will be equal
According to the American medical website reported that the current international API market products can be divided into two categories, namely chemical synthetic medicine and biological engineering, medicine, the former accounts for roughly 90% of the total international API, only 10% of the latter, it is still visible chemical synthetic medicine unify the whole country.
But it must be pointed out that more and more European and American pharmaceutical manufacturers in abandoning the traditional chemical synthesis () API production, focus on developing biological engineering (recombinant DNA and protein) API product, because the latter is more profitable. By western pharmaceutical manufacturers give up most of the active pharmaceutical ingredients product price is low, the production will cause serious environmental pollution and so on, this is also our API products (mainly for active pharmaceutical ingredients, plant extraction plant-based products accounted for a small) background of export growth in recent years.
In fact, Chinese drug companies, although they have a wide range of export products in the international market, the actual operating income of the main pharmaceutical manufacturers in China is not very high compared with their western counterparts. According to foreign media reports, the biggest western API manufacturing enterprises Israel's TEVA pharmaceutical industry up to more than 300 species of perennial production of API products in the company, in 2016 total revenue of $21.9 billion. The total operating income of the six major pharmaceutical manufacturers in China is also not worth the Israeli company.
Swiss company operating income is as high as $2015 in 50.3 billion, its name Sandoz company specializing in active pharmaceutical ingredients, products ranging from amlodipine, cetirizine, omeprazole, force new cephalosporin, ibuprofen, etc "fair" to penicillium carbon alkene new varieties, the products and product competition is not much advantage in our country, so the Sandoz has shut down at the end of 2016 in mumbai and Hamburg, Germany, several of the API production line, the increased in Poland and Africa namibia API production capacity, in order to improve the competitiveness of the company in the international market.
India Dr Reddy pharmaceutical factory (hereinafter referred to as "reddy company") is the second after Japan in the American stock exchange listed pharmaceutical companies in Asia, by listing of dongfeng, brady conveniently launched his company development and production of a variety of chemical active pharmaceutical ingredients and intermediates, smoothly into the European market. In 2016, redi's net profit was $330 million, far more than any other drug company in China.
In the future, it will be harder and harder to rely solely on the export of raw materials, especially synthetic ones. Only in the case of rudi, not only is there a variety of raw materials, but more importantly, the production of raw materials and the preparation of the preparation will help you to live a better life. Novartis, a Swiss firm, would have died if its Sandoz company had made it.
|
